<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04196673</url>
  </required_header>
  <id_info>
    <org_study_id>1560/2014</org_study_id>
    <nct_id>NCT04196673</nct_id>
  </id_info>
  <brief_title>Posterior Capsule Opafication of Two Different Hydrophobic Acrylic Intraocular Lenses</brief_title>
  <acronym>Acryvivi</acronym>
  <official_title>Posterior Capsule Opafication of Two Different Hydrophobic Acrylic Intraocular Lenses: Vivinex iSert P261 vs. Acrysof SN60WF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      On the day of surgery, the first eye to be operated is randomised to receive a Vivinex , HOYA
      Surgical Optics GmbH or an SN60WF, Alcon, Fort Worth, Texas. The second eye to be operated
      receives the other IOL type.

      A complete biomicroscopic examination, visual acuity testing using autorefractometer,
      contrast sensitivity testing, and standardised retroillumination photography for PCO
      evaluation, will be performed 6 month (30-60 days), 1.5 years (± 3 months) and 3 (± 3 months)
      years postoperatively.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2015</start_date>
  <completion_date type="Actual">August 23, 2019</completion_date>
  <primary_completion_date type="Actual">June 19, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The investigational devices are approved intraocular lenses (IOLs) intended to be implanted after phacoemulsification in individuals suffering from age-related cataract with the need of cataract surgery. Cataract surgery with precedent bilateral randomized IOL implantation will be performed in subjects who have signed an informed consent form. Postoperative examinations will be implemented in accordance with the approved Investigational Plan on subjects and includes: visual acuity, slitlamp examination, fibrosis, posterior capsule opacification (PCO) score and YAG capsulotomy rate.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PCO score</measure>
    <time_frame>3 years</time_frame>
    <description>subjectively and objectively graded: 0-10 (0= no PCO, 10= maximum PCO)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>3 years</time_frame>
    <description>UCDVA(uncorrected distance visual acuity), BCDVA (best corrected distance visual acuity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrosis</measure>
    <time_frame>3 years</time_frame>
    <description>grade of fibrosis assessed subjectively at the slitlamp (grade 0=no fibrosis, grade 3=maximum fibrosis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective glistening score</measure>
    <time_frame>3 years</time_frame>
    <description>neg, &lt;10, 10-20, 20-30, 30-40, &gt;40 uniform or localized</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>YAG capsulotomy rate</measure>
    <time_frame>3 years</time_frame>
    <description>described subjectively at the slitlamp: was a YAG capsulotomy performed yes/no</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Age Related Cataracts</condition>
  <arm_group>
    <arm_group_label>Alcon SN60WF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of an intraocular lens Alcon SN60WF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hoya Vivinex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of an intraocular lens Hoya Vivinex</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Alcon SN60WF</intervention_name>
    <description>Implantation of an intraocular lens Alcon SN60WF</description>
    <arm_group_label>Alcon SN60WF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hoya Vivinex</intervention_name>
    <description>Implantation of an intraocular lens Hoya Vivinex</description>
    <arm_group_label>Hoya Vivinex</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Bilateral age-related cataract for which phacoemulsification extraction and posterior
             IOL implantation has planned

          -  Age 50 and older

          -  Visual potential in both eyes of 20/30 or better as determined by investigators
             estimation

          -  Normal findings in the medical history and physical examination unless the
             investigator considers an abnormality to be clinically irrelevant

        Exclusion Criteria:

          -  Preceding intraocular surgery or ocular trauma

          -  Relevant other ophthalmic diseases (such as pseudoexfoliation, glaucoma, uveitis,
             retinal degenerations, etc.)

          -  Laser treatment

          -  Uncontrolled systemic or ocular disease

          -  Infectious disease

          -  Pregnancy/Nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rupert Menapace, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 6, 2019</study_first_submitted>
  <study_first_submitted_qc>December 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>December 11, 2019</last_update_submitted>
  <last_update_submitted_qc>December 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Rupert Menapace</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

